Lasofoxifene in Phase III nears full enrollment for ESR1-mutated breast cancer
LeonaBio’s lasofoxifene is advancing in a pivotal Phase III trial in ESR1-mutated metastatic breast cancer, with enrollment nearing completion.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.